CD14型
细胞生物学
树突状细胞
祖细胞
造血
脐带血
单核细胞
免疫学
生物
免疫系统
化学
干细胞
作者
Soo Ji Kim,Girak Kim,Narae Kim,Hyuk Chu,Byung‐Chul Park,Jae Seung Yang,Cheol‐Heui Yun,Cheol‐Heui Yun
出处
期刊:Cytotherapy
[Elsevier BV]
日期:2019-10-01
卷期号:21 (10): 1049-1063
被引量:11
标识
DOI:10.1016/j.jcyt.2019.07.007
摘要
Human CD141+ dendritic cells (DCs), specialized for cross-presentation, have been extensively studied in the development of DC-based therapy against cancer. A series of attempts was made to generate CD141+ DCs from cord blood CD34+ hematopoietic progenitors to overcome the practical limitation of in vivo rareness. In the present study, we identified a culture system that generates high CD141+ DCs. After culture of CD14+ monocytes in the presence of granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4 for 8 days, CD141 was detected on cells that adhered to the bottom of the culture plate. The attached cells exhibited typical features of immature monocyte-derived DCs (moDCs), except for higher CD86 expression, more dendrites and higher granularity compared with those that did not attach. With 3 additional days of culture, increased CD141 expression on the cells was retained along with adhesion ability and partial expression of CLEC9A, a c-type lectin receptor. Furthermore, the cells exhibited effective uptake of dead cells. Interestingly, the attached moDCs differently responded to polyinosinic:polycytidylic acid (poly I:C) stimulation as well as a mixed lymphocyte reaction. Collectively, our findings show that human CD141+ DCs can be sufficiently generated from peripheral blood CD14+ monocytes, potentiating further investigation into generation of higher yields of cross-priming human DCs in vitro.
科研通智能强力驱动
Strongly Powered by AbleSci AI